Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Demographic and Clinical Characteristics
3.2. Relapse Profile and Timing
3.3. Clinical Presentation at Onset
3.4. Neurological Impairment During Relapses
- Group 1 had four children with unilateral deficiency throughout three to five events;
- Group 3 had seven children with similar motor dysfunction during one event. In all research groups, bilateral deficiency is uncommon.
- While 35 late-onset individuals had between 1 and 4 sensory disturbance episodes, most Group 1 and 2 patients had 1–2 episodes.
- Of the early-onset MS kids, nearly half (5) experienced between 1 and 8 episodes of balance problems; 20 from Group 3 had 1–3 episodes. Of Group 3, 21 individuals have optic neuritis during 1 to 4 episodes, which is less common in the other two age-related groups.
- Cranial nerve involvement seems more common in Groups 1 and 3—1–3 attacks; in Group 2, however, four people suffer this impairment in 1 to 4 relapses.
- Early onset (three individuals) is more frequent for ADEM-like appearance, while intracranial hypertension syndrome is more prevalent in late-onset participants with tumefactive or prolonged lesions (Table 1).
3.5. CSF and MRI Findings
3.6. Therapies and Treatment Response
3.7. Disability and Cognitive Outcomes
- Group 1: 6/11 had EDSS 0, 4 had mild impairment (EDSS 1–2), and 1 had severe disability.
- Group 2: 7/10 were fully functional (EDSS 0), 2 had mild, and 1 had severe impairment.
- Group 3: ~10% had EDSS 1–2; three had moderate, and five had severe impairment.
3.8. Neuropsychological Outcomes
- Group 1: two children with borderline intelligence, two with mild intellectual disability, and others with executive and learning deficits.
- Group 2: four with borderline intelligence, two with MS-related anxiety and depression.
- Group 3: 4 with mild intellectual disability, 1 with severe cognitive impairment, and 30 with associated depression.
4. Discussion
4.1. Limitations
4.2. Future Research Directions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
CFS | Cerebral fluid spine |
DMT | Disease-modifying therapy |
ICH | Intracranial hypertension syndrome |
MRI | Magnetic Resonance Imaging |
POMS | Pediatric Multiple sclerosis |
References
- Chitnis, T.; Glanz, B.; Jaffin, S.; Healy, B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult. Scler. 2009, 15, 627–631. [Google Scholar] [CrossRef]
- Krupp, L.B.; Tardieu, M.; Amato, M.P.; Banwell, B.; Chitnis, T.; Dale, R.C.; Ghezzi, A.; Hintzen, R.; Kornberg, A.; Pohl, D.; et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions. Mult. Scler. 2013, 19, 1261–1267. [Google Scholar] [CrossRef]
- Brola, W.; Steinborn, B. Pediatric multiple sclerosis—Current status of epidemiology, diagnosis and treatment. Neurol. Neurochir. Polska 2020, 54, 508–517. [Google Scholar] [CrossRef] [PubMed]
- Luca, M.; Ortega-Castro, N.; Patti, F. Paediatric Multiple Sclerosis: A Scoping Review of Patients’ and Parents’ Perspectives. Children 2021, 9, 11. [Google Scholar] [CrossRef]
- Ramphul, K.; Mejias, S.G.; Joynauth, J. Pediatric multiple sclerosis in the United States in children ages 0-18. Mult. Scler. Relat. Disord. 2020, 38, 101874. [Google Scholar] [CrossRef] [PubMed]
- Alroughani, R.; Boyko, A. Pediatric multiple sclerosis: A review. BMC Neurol. 2018, 18, 27. [Google Scholar] [CrossRef] [PubMed]
- Margoni, M.; Rinaldi, F.; Perini, P.; Gallo, P. Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities. Front. Neurol. 2021, 12, 676095. [Google Scholar] [CrossRef]
- Ghezzi, A.; Baroncini, D.; Zaffaroni, M.; Comi, G. Pediatric versus adult MS: Similar or different? Mult. Scler. Demyelinating Disord. 2017, 2, 5. [Google Scholar] [CrossRef]
- Jakimovski, D.; Awan, S.; Eckert, S.P.; Farooq, O.; Weinstock-Guttman, B. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs 2022, 36, 45–59. [Google Scholar] [CrossRef]
- Boiko, A.; Vorobeychik, G.; Paty, D.; Devonshire, V.; Sadovnick, D. University of British Columbia MS Clinic Neurologists Early onset multiple sclerosis: A longitudinal study. Neurology 2002, 59, 1006–1010. [Google Scholar] [CrossRef]
- Renoux, C.; Vukusic, S.; Mikaeloff, Y.; Edan, G.; Clanet, M.; Dubois, B.; Debouverie, M.; Brochet, B.; Lebrun-Frenay, C.; Pelletier, J.; et al. Natural history of multiple sclerosis with childhood onset. N. Engl. J. Med. 2007, 356, 2603–2613. [Google Scholar] [CrossRef] [PubMed]
- Gorman, M.P.; Healy, B.C.; Polgar-Turcsanyi, M.; Chitnis, T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch. Neurol. 2009, 66, 54–59. [Google Scholar] [CrossRef]
- Amato, M.P.; Goretti, B.; Ghezzi, A.; Hakiki, B.; Niccolai, C.; Lori, S.; Moiola, L.; Falautano, M.; Viterbo, R.G.; Patti, F.; et al. Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up. Neurology 2014, 83, 1432–1438. [Google Scholar] [CrossRef]
- Waldman, A.; Ness, J.; Pohl, D.; Simone, I.L.; Anlar, B.; Amato, M.P.; Ghezzi, A. Pediatric multiple sclerosis: Clinical features and outcome. Neurology 2016, 87, S74–S81. [Google Scholar] [CrossRef] [PubMed]
- Linca, F.I.; Budisteanu, M.; Popovici, D.V.; Cucu, N. The Moderating Role of Emotional Regulation on the Relationship between School Results and Personal Characteristics of Pupils with Attention Deficit/Hyperactivity Disorder. Children 2022, 9, 1637. [Google Scholar] [CrossRef]
- Kauth, F.; Bertolini, A.; Wendel, E.-M.; Koukou, G.; Naggar, I.E.; Chung, J.; Baumann, M.; Schödl, C.; Lechner, C.; Bigi, S.; et al. Characterization of children with early onset pediatric multiple sclerosis. Eur. J. Paediatr. Neurol. 2025, 54, 113–120. [Google Scholar] [CrossRef] [PubMed]
- Huppke, B.; Ellenberger, D.; Rosewich, H.; Friede, T.; Gärtner, J.; Huppke, P. Clinical presentation of pediatric multiple sclerosis before puberty. Eur. J. Neurol. 2014, 21, 441–446. [Google Scholar] [CrossRef] [PubMed]
- Özdemir, A.; Poyraz, C.A.; Erten, E.; Çırakoğlu, E.; Tomruk, N. Electroconvulsive Therapy in Women: A Retrospective Study from a Mental Health Hospital in Turkey. Psychiatr. Q. 2016, 87, 769–779. [Google Scholar] [CrossRef]
- Carvalho, I.V.; Dos Santos, C.S.; Amaral, J.; Ribeiro, J.A.; Pereira, C.; Pais, R.P.; Palavra, F. Multiple sclerosis under the age of ten: The challenge of a rare diagnosis in a special population—A case series. Front. Neurosci. 2023, 17, 1297171. [Google Scholar] [CrossRef]
- Rad, F.; Stancu, M.; Andrei, L.-E.; Linca, F.-I.; Mariana Buică, A.; Leti, M.-M.; Dobrescu, I.; Mihailescu, I.; Efrim-Budisteanu, M. Diagnosis stability and outcome of psychotic episodes in a Romanian group of children and adolescents. Medicine 2022, 101, e30288. [Google Scholar] [CrossRef]
- Verhey, L.H.; Branson, H.M.; Shroff, M.M.; Callen, D.J.; Sled, J.G.; Narayanan, S.; Sadovnick, A.D.; Bar-Or, A.; Arnold, D.L.; Marrie, R.A.; et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: A prospective national cohort study. Lancet Neurol. 2011, 10, 1065–1073. [Google Scholar] [CrossRef]
- Reinhardt, K.; Weiss, S.; Rosenbauer, J.; Gärtner, J.; von Kries, R. Multiple sclerosis in children and adolescents: Incidence and clinical picture—New insights from the nationwide German surveillance (2009–2011). Eur. J. Neurol. 2014, 21, 654–659. [Google Scholar] [CrossRef]
- Deiva, K. Pediatric onset multiple sclerosis. Rev. Neurol. 2020, 176, 30–36. [Google Scholar] [CrossRef] [PubMed]
- Langille, M.M.; Rutatangwa, A.; Francisco, C. Pediatric Multiple Sclerosis: A Review. Adv. Pediatr. 2019, 66, 209–229. [Google Scholar] [CrossRef] [PubMed]
- Bove, R.; Rankin, K.; Lin, C.; Zhao, C.; Correale, J.; Hellwig, K.; Michel, L.; Laplaud, D.A.; Chitnis, T. Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis. Mult. Scler. J. 2020, 26, 1410–1419. [Google Scholar] [CrossRef] [PubMed]
- Stanciu, A.C.; Rad, F.; Mihailescu, I.; Mateescu, L.; Grozavescu, R.; Andrei, E.; Budisteanu, B.; Linca, F.; Ioana, D.; Iliescu, C.; et al. Multidisciplinary approach in children with autism spectrum disorder. Eur. Psychiatry 2021, 64, S86. [Google Scholar] [CrossRef]
- Iliuta, F.P.; Manea, M.C.; Budisteanu, M.; Andrei, E.; Linca, F.; Rad, F.; Cergan, R.; Ciobanu, A.M. Magnetic resonance imaging of brain anomalies in adult and pediatric schizophrenia patients: Experience of a Romanian tertiary hospital. Exp. Ther. Med. 2021, 22, 1098. [Google Scholar] [CrossRef]
- Budisteanu, M.; Linca, F.; Andrei, L.E.; Mateescu, L.; Glangher, A.; Ioana, D.; Severin, E.; Riga, S.; Rad, F. Recognition of early warning signs and symptoms—The first steps on the road to Autism Spectrum Disorder diagnosis. Ann. Ist. Super. Sanita 2022, 58, 183–191. [Google Scholar] [CrossRef]
- Linca, F.; Alexandrescu, L.; Cucu, N.; Alexandrescu, B. Investigation of FTO Gene-BMI Association in a Romanian Sample: A Functional Genomic Interpretation. Biointerface Res. Appl. Chem. 2022, 13, 230. [Google Scholar] [CrossRef]
- Mikaeloff, Y.; Caridade, G.; Assi, S.; Suissa, S.; Tardieu, M. Prognostic factors for early severity in a childhood multiple sclerosis cohort. Pediatrics 2006, 118, 1133–1139. [Google Scholar] [CrossRef]
- Fay, A.J.; Mowry, E.M.; Strober, J.; Waubant, E. Relapse severity and recovery in early pediatric multiple sclerosis. Mult. Scler. 2012, 18, 1008–1012. [Google Scholar] [CrossRef] [PubMed]
- Akhtar, S.; Alroughani, R.; Ahmed, S.F.; Al-Hashel, J.Y. Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait. Mult. Scler. 2016, 22, 1086–1093. [Google Scholar] [CrossRef]
- McKay, K.A.; Hillert, J.; Manouchehrinia, A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology 2019, 92, e2764–e2773. [Google Scholar] [CrossRef] [PubMed]
- Chitnis, T.; Aaen, G.; Belman, A.; Benson, L.; Gorman, M.; Goyal, M.S.; Graves, J.S.; Harris, Y.; Krupp, L.; Lotze, T.; et al. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain 2020, 143, 2733–2741. [Google Scholar] [CrossRef]
- Nicotera, A.G.; Spoto, G.; Saia, M.C.; Midiri, M.; Turriziani, L.; Amore, G.; Di Rosa, G. Treatment of multiple sclerosis in children: A brief overview. Clin. Immunol. 2022, 237, 108947. [Google Scholar] [CrossRef] [PubMed]
- Forrester, M.B.; Coleman, L.; Kornberg, A.J. Multiple sclerosis in childhood: Clinical and radiological features. J. Child. Neurol. 2009, 24, 56–62. [Google Scholar] [CrossRef]
- Ghezzi, A.; Pozzilli, C.; Liguori, M.; Marrosu, M.G.; Milani, N.; Milanese, C.; Simone, I.; Zaffaroni, M. Prospective study of multiple sclerosis with early onset. Mult. Scler. 2002, 8, 115–118. [Google Scholar] [CrossRef]
- Aaen, G.; Waltz, M.; Vargas, W.; Makhani, N.; Ness, J.; Harris, Y.; Casper, T.C.; Benson, L.; Candee, M.; Chitnis, T.; et al. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. J. Child. Neurol. 2019, 34, 148–152. [Google Scholar] [CrossRef]
- Julian, L.; Serafin, D.; Charvet, L.; Ackerson, J.; Benedict, R.; Braaten, E.; Brown, T.; O’Donnell, E.; Parrish, J.; Preston, T.; et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: Results from a United States network. J. Child. Neurol. 2013, 28, 102–107. [Google Scholar] [CrossRef]
- Till, C.; Ghassemi, R.; Aubert-Broche, B.; Kerbrat, A.; Collins, D.L.; Narayanan, S.; Arnold, D.L.; Desrocher, M.; Sled, J.G.; Banwell, B.L. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology 2011, 25, 319–332. [Google Scholar] [CrossRef]
- Govindarajan, S.T.; Liu, Y.; Parra Corral, M.A.; Bangiyev, L.; Krupp, L.; Charvet, L.; Duong, T.Q. White matter correlates of slowed information processing speed in unimpaired multiple sclerosis patients with young age onset. Brain Imaging Behav. 2021, 15, 1460–1468. [Google Scholar] [CrossRef] [PubMed]
- Hacohen, Y.; Banwell, B.; Ciccarelli, O. What does first-line therapy mean for paediatric multiple sclerosis in the current era? Mult. Scler. 2021, 27, 1970–1976. [Google Scholar] [CrossRef]
- Tarantino, S.; Proietti Checchi, M.; Papetti, L.; Monte, G.; Ferilli, M.A.N.; Valeriani, M. Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: A narrative review. Neurol. Sci. 2024, 45, 1913–1930. [Google Scholar] [CrossRef] [PubMed]
- Silveira, C.; Guedes, R.; Maia, D.; Curral, R.; Coelho, R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019, 16, 877–888. [Google Scholar] [CrossRef]
- Boesen, M.S.; Thygesen, L.C.; Uldall, P.V.; Eriksson, F.; Born, A.P.; Blinkenberg, M.; Koch-Henriksen, N.; Greisen, G.; Magyari, M. Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study. Mult. Scler. Relat. Disord. 2018, 19, 30–34. [Google Scholar] [CrossRef] [PubMed]
- Meier, U.-C.; Ramagopalan, S.V.; Goldacre, M.J.; Goldacre, R. Risk of Schizophrenia and Bipolar Disorder in Patients With Multiple Sclerosis: Record-Linkage Studies. Front. Psychiatry 2020, 11, 662. [Google Scholar] [CrossRef] [PubMed]
- Pakpoor, J.; Goldacre, R.; Schmierer, K.; Giovannoni, G.; Waubant, E.; Goldacre, M.J. Psychiatric disorders in children with demyelinating diseases of the central nervous system. Mult. Scler. 2018, 24, 1243–1250. [Google Scholar] [CrossRef]
- Kozłowska, A.; Wojtacha, P.; Równiak, M.; Kolenkiewicz, M.; Huang, A.C.W. ADHD pathogenesis in the immune, endocrine and nervous systems of juvenile and maturating SHR and WKY rats. Psychopharmacology 2019, 236, 2937–2958. [Google Scholar] [CrossRef]
- Fragoso, Y.D. Specificities of Children with Multiple Sclerosis and Neuromyelitis Optica. Central Nerv. Syst. Agents Med. Chem. 2018, 18, 16–20. [Google Scholar] [CrossRef]
- Pratt, L.-T.; Meirson, H.; Shapira Rootman, M.; Ben-Sira, L.; Shiran, S.I. Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease-diagnostic criteria and lesion dynamics. Pediatr. Radiol. 2025, 55, 699–720. [Google Scholar] [CrossRef]
- Palavra, F.; Silva, D.; Fernandes, C.; Faustino, R.; Vasconcelos, M.; Pereira, C.; Costa, C.; Ribeiro, J.A.; Amaral, J.; Robalo, C. Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: An exploratory single-center study. Front. Neurosci. 2023, 17, 1259306. [Google Scholar] [CrossRef] [PubMed]
- Naggar, A.; Laasri, K.; Kabila, B.; Izi, Z.; Allali, N.; Haddad, S.E.; Chat, L. Myelin insults differentials on MRI in children: In the light of an ADEM case. Radiol. Case Rep. 2024, 19, 408–413. [Google Scholar] [CrossRef]
- Afanasjeva, B.; Afanasjevas, D.; Endzinienė, M.; Balnytė, R. Characteristics of the Manifestation of Multiple Sclerosis in Children in Lithuania. Medicina 2023, 59, 1055. [Google Scholar] [CrossRef]
- Krysko, K.M.; Graves, J.; Rensel, M.; Weinstock-Guttman, B.; Aaen, G.; Benson, L.; Chitnis, T.; Gorman, M.; Goyal, M.; Krupp, L.; et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology 2018, 91, e1778–e1787. [Google Scholar] [CrossRef]
- Fadda, G.; Armangue, T.; Hacohen, Y.; Chitnis, T.; Banwell, B. Paediatric multiple sclerosis and antibody-associated demyelination: Clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 2021, 20, 136–149. [Google Scholar] [CrossRef] [PubMed]
- Fisher, K.S.; Cuascut, F.X.; Rivera, V.M.; Hutton, G.J. Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines 2020, 8, 71. [Google Scholar] [CrossRef]
- Glangher, A.; Budișteanu, M.; Bârcă, D.; Șurlică, D.; Lincă, F.I.; Ioana, D.; Bohîlțea, L.-C.; Focșa, I.-O.; Iliescu, C. Epileptic Encephalopathy Related to CAD Deleterious Variants—A Case Series. Diseases 2025, 13, 91. [Google Scholar] [CrossRef] [PubMed]
- Hammond, J.W.; Bellizzi, M.J.; Ware, C.; Qiu, W.Q.; Saminathan, P.; Li, H.; Luo, S.; Ma, S.A.; Li, Y.; Gelbard, H.A. Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav. Immun. 2020, 87, 739–750. [Google Scholar] [CrossRef]
- Lanzillo, R.; Chiodi, A.; Carotenuto, A.; Magri, V.; Napolitano, A.; Liuzzi, R.; Costabile, T.; Rainone, N.; Freda, M.F.; Valerio, P.; et al. Quality of life and cognitive functions in early onset multiple sclerosis. Eur. J. Paediatr. Neurol. 2016, 20, 158–163. [Google Scholar] [CrossRef]
- Rosa, L.; Petracca, M.; Carotenuto, A.; Dolce, P.; Piscopo, K.; Dicé, F.; Lauro, F.; Spiezia, A.L.; Moccia, M.; Lavorgna, L.; et al. Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study. J. Clin. Med. 2022, 11, 5226. [Google Scholar] [CrossRef]
- Rojas, J.I.; Patrucco, L.; Miguez, J.; Cristiano, E. Brain atrophy in multiple sclerosis: Therapeutic, cognitive and clinical impact. Arq. Neuropsiquiatr. 2016, 74, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Trust, M.S. Expanded Disability Status Scale (EDSS)|MS Trust. Available online: https://mstrust.org.uk/a-z/expanded-disability-status-scale-edss (accessed on 6 April 2025).
Item | Group 1 (<10 year) | Group 2 (10–12 year) | Group 3 (>12 year) |
---|---|---|---|
Gender (female:male ratio) | 1:2 | 1:1 | 2:1 |
Age of onset | 11 | 10 | 99 |
Age of MS diagnosis | 5 | 8 | 107 |
Duration onset-dg (months) | |||
<6 mo | 4 | 4 | 74 |
>6 mo | 7 | 6 | 25 |
Reasons for delay dg | |||
Incomplete McDonald crit | 3 | 4 | 11 |
Incomplete investigation | 3 | 1 | 8 |
Atypical presentation | 1 | 0 | 3 |
Late hospital presentation | 2 | 2 | 11 |
MS type | |||
RRMS | 9 | 6 | 62 |
CIS | 2 | 4 | 37 |
Relapses number | |||
Relapse nr before diagnosis | 1–3 p; 2–7 p; 3–1 p | 1–7 p; 2–0 p; 3–3 p | 1–62 p; 2–30 p; 3/4–6/1 p |
Relapse nr between diagnosis–treatment | 0–5 p; 1–2 p; 2/4–2 p | 0–6 p; 1–3 p; 2–0 p | 0–62 p; 1–12 p; 2/3–5/2 p |
Total nr of relapses | 1–2 p; 2/3–3/1 p; 5->10–5 p; 16–1 p | 1–4 p; 2–1 p; 3->8–5 p | 1–38; 2–26 p; 3–15 p; 4->6–20 p |
Duration 1st–2nd relapse (months) | |||
<6 mo | 2 | 2 | 30 |
6–12 mo | 3 | 1 | 13 |
12–36 mo | 1 | 1 | 16 |
>36 mo | 3 | 2 | 3 |
Clinical picture at onset (1st event) | |||
Multifocal | 4 | 2 | 33 |
Unilateral deficit | 5 | 5 | 35 |
Bilateral deficit | 0 | 0 | 7 |
Balance disturbances | 2 | 4 | 17 |
Cranial nerve palsy | 4 | 3 | 20 |
Sensitivity disorder | 0 | 0 | 32 |
ON | 3 (2 bilat) | 1 bilat | 28 |
ADEM/ICH-like sy | 3 | 0 | 2 |
Clinical features during relapses | |||
Unilateral deficit | 1->3 ep/4 p 5->8 ep/2 p | 1->2 ep/3 p 3 ep/1 p | 1 ep/19 p 2 ep/7 p |
Bilateral deficit | 1 ep/2 p 4 ep/1 p | 0 | 1 ep/2 p |
Balance disturbances | 1->3 ep/3 p 6->8 ep/2 p | 3 ep/2 p | 1 ep/15 p 2->3 ep/7 p |
Cranial nerve palsy | 1 ep/1 p 3 ep/3 p | 1->2 ep/2 p | 1 ep/16 p 2->4 ep/6 p |
Sensitivity disorder | 1->2 ep/5 p | 1 ep/2 p | 1 ep/22 p 2->3 ep/11 p |
ON | 0 | 1->2 ep/2 p 4 ep/1 p | 1 ep/15 p 2->3 ep/4 p |
ADEM/ICH-like sy | 1->3 ep/3 p | 0 | 0 |
Oligoclonal bands | |||
Positive (+) | 7 | 8 | 81 |
Initial chronic treatment | |||
IG | 1 | 1 | 0 |
Cortisone | 1 | 0 | 0 |
IFNb | 5 | 3 | 76 |
Fingolimod | 2 | 4 | 3 |
RTX | 0 | 1 | 0 |
Dimetyl fumarate | 0 | 0 | 1 |
Actual chronic treatment | |||
IFNb | 2 | 3 | 74 |
Fingolimod | 4 | 5 | 5 |
RTX | 1 | 2 | 0 |
Dimetyl fumarate | 0 | 0 | 1 |
Nr of chronic treatments | |||
0–1 p; 1–6 p 2–1 p; 3–2 p | 0–1 p; 1–7 p 2–1 p; 4–1 p | 0–20 p;2–5 p 1–74 p | |
EDSS 6mo-3 year after dg | |||
0 | 7 | 8 | 85 |
1–2 | 2 | 1 | 9 |
2.5–3 | 2 | 1 | 2–5 |
>3 | 0 | 0 | 1 |
EDSS at 1–3 year of trat | |||
0 | 7 | 8 | 92 |
1–2 | 2 | 2–1 | 9–4 |
2.5–3 | 0 | 0 | 2 |
>3 | 1 | 1 | 2–1 |
Actual/Last EDSS | |||
0 | 6 | 7 | 81 |
1–2 | 4 | 2 | 10 |
2.5–3 | 0 | 0 | 5 |
>3 | 1 | 1 | 3 |
Cognitive problems | |||
Normal intellect but learning difficulties | 11 | 10 | 19 |
Borderline | 2 | 4 | 10 |
Mild disability | 2 | 0 | 4 |
Moderate disability | 0 | 0 | 0 |
Severe disability | 0 | 0 | 1 |
Depression/anxiety | 0 | 2 | 30 |
MRI at the first episode | |||
Brain—nr of lesions | |||
5–10 | 6 | 5 | 64 |
>10 | 4 | 4 | 23 |
Spine—nr of lesions | |||
1–3 | 8 | 10 | 91 |
4–6 | 1 | 0 | 0 |
>6 | 0 | 0 | 7 |
MRI at 1 year with the treat | |||
Brain—nr of lesions | |||
1–3 | 4–0 | 5–3 | 28–4 |
4–6 | 2–0 | 2–0 | 18–3 |
7–10 | 2–0 | 1–0 | 8–1 |
>10 | |||
Spine—nr of lesions | |||
1–3 | 4–1 | 6–2 | 37–6 |
4–6 | 2–1 | 2–1 | 13–3 |
Χ2 | df | p | |
---|---|---|---|
Current EDSS _ final monitoring period when turning 18 years old | 9.346 | 6 | 0.155 |
duration between attacks1_attack2 | 22.215 | 12 | 0.035 |
EDSS 6 months after dg | 12.122 | 6 | 0.059 |
EDSS 1 year after dg | 14.204 | 8 | 0.077 |
EDSS 2 years after dg | 11.270 | 8 | 0.187 |
EDSS 3 years after dg | 14.833 | 8 | 0.062 |
EDSS 4 years after dg | 40.441 | 8 | <0.001 |
EDSS 5 years after dg | 52.469 | 8 | <0.001 |
EDSS 6 years after dg | 37.476 | 6 | <0.001 |
EDSS 7 years after dg | 14.644 | 4 | 0.005 |
EDSS at 1st year of treatment | 12.447 | 8 | 0.132 |
EDSS at 2nd year of treatment | 6.568 | 8 | 0.584 |
EDSS at 3rd year of treatment | 12.210 | 8 | 0.142 |
EDSS at 4th year of treatment | 32.052 | 6 | <0.001 |
EDSS at 5th year of treatment | 22.556 | 6 | <0.001 |
EDSS at 6th year of treatment | 11.092 | 2 | 0.004 |
EDSS at 7th year of treatment | 21.148 | 10 | 0.020 |
Current EDSS | 13.579 | 10 | 0.193 |
Duration between flares under treat 1 | 25.468 | 10 | 0.005 |
no new brain lesions—first MRI | 7.414 | 6 | 0.284 |
no new spinal cord lesions—first MRI | 21.054 | 4 | 0.615 |
no new brain lesions—MRI at 7 year form treat | 42.470 | 6 | <0.001 |
no new spinal cord lesions—first MRI at 7 year form treat | 42.470 | 4 | <0.001 |
no new brain lesions—MRI at 6 mo after dg | 7.284 | 8 | 0.506 |
no new spinal cord lesions—MRI at 6 mo after dg | 2.722 | 4 | 0.605 |
no relapses until diagnosis | 4.718 | 2 | 0.048 |
no total relapses | 5.218 | 2 | 0.047 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dică, A.D.; Craiu, D.; Linca, F.I.; Budișteanu, M.; Iliescu, C.; Sandu, C.; Pomeran, C.; Bârcă, D.; Butoianu, N.; Burloiu, C.; et al. Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience. Diseases 2025, 13, 193. https://doi.org/10.3390/diseases13070193
Dică AD, Craiu D, Linca FI, Budișteanu M, Iliescu C, Sandu C, Pomeran C, Bârcă D, Butoianu N, Burloiu C, et al. Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience. Diseases. 2025; 13(7):193. https://doi.org/10.3390/diseases13070193
Chicago/Turabian StyleDică, Alice Denisa, Dana Craiu, Florentina Ionela Linca, Magdalena Budișteanu, Catrinel Iliescu, Carmen Sandu, Cristina Pomeran, Diana Bârcă, Niculina Butoianu, Carmen Burloiu, and et al. 2025. "Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience" Diseases 13, no. 7: 193. https://doi.org/10.3390/diseases13070193
APA StyleDică, A. D., Craiu, D., Linca, F. I., Budișteanu, M., Iliescu, C., Sandu, C., Pomeran, C., Bârcă, D., Butoianu, N., Burloiu, C., Minciu, I., Focșa, I. O., Surlică, D., Tarța-Arsene, O., Cazacu, C., Badea, A., Niculae, A. S., & Ion, D. A. (2025). Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience. Diseases, 13(7), 193. https://doi.org/10.3390/diseases13070193